- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07940192
Phenotype of Alcohol-Related Nutritional Sensory Neuronopathies and Comparison With Dysimmune and Paraneoplastic Forms (NNS-OH)
Sensory neuronopathies (SNNs) are rare disorders characterized by damage to sensory neurons in the dorsal root ganglia. They may have dysimmune, paraneoplastic, toxic, or genetic causes. Alcohol-related nutritional sensory neuronopathy has recently been described and may present acutely or subacutely with pain, mimicking dysimmune or paraneoplastic disease. Distinguishing these causes early may help guide appropriate management. This international, multicentre, retrospective observational cohort study will describe the initial and follow-up clinical and electrophysiological phenotype of acute/subacute alcohol-related nutritional SNN and compare it with dysimmune and paraneoplastic SNN. Data will be abstracted from existing medical records. The protocol anticipates approximately 75 participants with alcohol-related nutritional SNN, 50 with dysimmune SNN, and 20 with paraneoplastic SNN. No additional procedure is performed for research purposes and no direct benefit is expected for participants.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jean-Philippe CAMDESSANCHE, PUPH
- Phone Number: +33 04 77 12 78 05
- Email: j.philippe.camdessanche@chuse.fr
Study Locations
-
-
-
Brest, France, 29200
- CHU de Brest
-
Contact:
- Jean-Baptiste NOURY
- Phone Number: +33 02 98 22 33 33
- Email: jean-baptiste.noury@chu-brest.fr
-
Grenoble, France, 38500
- CHU de Grenoble
-
Contact:
- Martial Mallaret
- Phone Number: +33 04 76 76 75 75
- Email: MMallaret1@chu-grenoble.fr
-
Lille, France, 59000
- CHU de Lille
-
Contact:
- Céline TARD, Dr
- Phone Number: +33 03 20 44 59 62
- Email: CELINE.TARD@CHRU-LILLE.FR
-
Limoges, France, 87000
- CHU de Limoges
-
Contact:
- Laurent MAGY
- Phone Number: +33 05 55 05 55 55
- Email: Laurent.Magy@chu-limoges.fr
-
Montpellier, France, 34090
- CHU de Montpellier
-
Contact:
- Guillaume TAIEB
- Phone Number: +33 04 67 33 67 33
- Email: g-taieb@chu-montpellier.fr
-
Nantes, France, 44093
- CHU de Nantes
-
Contact:
- Yann PEREON
- Phone Number: +33 02 40 08 33 33
- Email: Yann.Pereon@univ-nantes.fr
-
Reims, France, 51100
- CHU de REIMS
-
Contact:
- Maxime Kirchhofer, Dr
- Phone Number: +33 03 26 78 78 78.
- Email: mkirchhofer@chu-reims.fr
-
-
France
-
Bordeaux, France, France, 33000
- CHU de Bordeaux
-
Contact:
- Guilhem SOLE, Dr
- Phone Number: +33 05.56.79.56.79
- Email: guilhem.sole@chu-bordeaux.fr
-
Créteil, France, France, 94000
- CHU Henri-Mondor
-
Contact:
- Thierry GENDRE, Dr
- Phone Number: + 33 01 49 81 21 11
- Email: thierry.gendre@aphp.fr
-
Garches, France, France, 92380
- AP-HP Hôpital Raymond-Poincaré
-
Contact:
- Edouard BERLING, Dr
- Phone Number: + 33 01 47 10 79 00
- Email: edouard.berling@aphp.fr
-
Le Kremlin-Bicêtre, France, France, 94270
- CHU de Bicetre
-
Contact:
- Guillemette BEAUDONNET, Dr
- Phone Number: + 33 01 45 21 21 21
- Email: guillemette.beaudonnet@aphp.fr
-
Marseille, France, France, 13005
- AP-HM Hôpital de la Timone
-
Contact:
- Emilien DELMONT, Dr
- Phone Number: +33 04 91 38 56 65
- Email: Emilien.DELMONT@ap-hm.fr
-
Paris, France, France, 75013
- AP-HP Hôpital Pitié-Salpêtrière
-
Contact:
- Thierry MAISONOBE, Dr
- Phone Number: +33 01 42 16 00 00
- Email: thierry.maisonobe@aphp.fr
-
Saint-Etienne, France, France, 42055
- CHU de Saint-Etienne
-
Contact:
- Jean-Philippe CAMDESSANCHE, PUPH
- Phone Number: + 33 04 77 12 78 05
- Email: j.philippe.camdessanche@chuse.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients monitored in a neurology department for their sensory neuropathies
Description
Inclusion Criteria :
- Age ≥ 18 years.
- Probable sensory neuronopathy according to the diagnostic criteria of Camdessanché et al.
- Acute or subacute onset (0-6 months).
- One of the following aetiologies: Alcohol-related nutritional SNN: chronic alcohol misuse (>100 g/week for at least 3 months) and/or biological markers of alcohol consumption, with dysimmune and paraneoplastic causes excluded. The minimum work-up includes an immune laboratory assessment including serum anti-neuronal antibodies, lumbar puncture, and thoraco-abdominal imaging. Dysimmune SNN: associated with Sjögren's syndrome, lupus, primary biliary cholangitis, anti-FGFR3 antibodies, or anti-AGO antibodies. Paraneoplastic SNN: associated with anti-Hu or anti-CV2/CRMP5 antibodies.
Exclusion Criteria :
- Exposure to platinum salts before the onset of sensory neuronopathy.
- Known hereditary neuropathy.
- Patient under guardianship or curatorship (tutelle or curatelle).
- Patient objection to the use of their data for the study.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: RETROSPECTIVE
Cohorts and Interventions
Group / Cohort |
|---|
|
Alcohol-related nutritional sensory neuronopathy
Adults with probable acute/subacute SNN attributed to chronic alcohol misuse (>100 g ethanol/week for at least 3 months) and/or biological markers of alcohol consumption, with dysimmune and paraneoplastic causes excluded using the minimum work-up specified in the protocol. |
|
Dysimmune sensory neuronopathy
Adults with probable acute/subacute SNN attributed to Sjögren's syndrome, lupus, primary biliary cholangitis, or associated with anti-FGFR3 or anti-AGO antibodies. |
|
Paraneoplastic sensory neuronopathy
Adults with probable acute/subacute SNN associated with anti-Hu or anti-CV2/CRMP5 antibodies. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Demographic and disease onset characteristics
Time Frame: from july 2006 to april 2027
|
Description of demographic characteristics and disease onset, including age at onset (years), mode of onset, and initial symptoms. Each variable will be reported individually, as available in the medical records. |
from july 2006 to april 2027
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jean-Phillippe CAMDESSANCHE, PUPH, CHU de Saint-Etienne
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- IRBN 154-2026/CHUSTE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.